Galapagos says GSK starting trials of its new drug
BRUSSELS (Reuters) - Belgian biotech company Galapagos said on Tuesday that its partner GlaxoSmithKline (GSK) planned to start Phase II studies into a drug candidate to treat two auto-immune disorders.
Galapagos said in a statement that GSK would launch the studies for compound GSK2586184 in systemic lupus erythematosus (SLE) and chronic plaque psoriasis.
Galapagos is eligible to receive 34 million euros in additional milestones plus up to double-digit percentage royalties on global sales. It is the second selective JAK1 molecule discovered by Galapagos to enter Phase 2 studies.
(Reporting by Philip Blenkinsop)
- Alabama man gets $1,000 in police settlement, his lawyers get $459,000
- New York police officer critically wounded in hatchet attack |
- Doctor with Ebola in NY hospital, nurse declared virus-free
- Exclusive: Charred tanks in Ukraine point to Russian involvement
- Putin accuses United States of damaging world order